Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
This article was originally published in The Pink Sheet Daily
Tentative agreement closely resembles FDA's original proposal.
You may also be interested in...
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions
Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.
How Do You Solve A Problem Like Sequestration?
FDA and advocates wait for OMB to clarify how the estimated 7.8% budget cut should be implemented, if it is enacted. Former agency officials say it could lead to hiring freezes and program delays.